Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis
<h3>Introduction</h3><p dir="ltr">While beta-blockers are considered the cornerstone of treatment for heart failure with reduced ejection fraction, the same may not apply to patients with heart failure with preserved ejection fraction (HFpEF). To date, the benefit of beta...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513529435914240 |
|---|---|
| author | Dr. Rasha Kaddoura (17823428) |
| author2 | Vichithranie Madurasinghe (3438182) Ammar Chapra (14777698) Dina Abushanab (10696501) Associate Prof. Daoud Al-Badriyeh (17823431) Ashfaq Patel (16855122) |
| author2_role | author author author author author |
| author_facet | Dr. Rasha Kaddoura (17823428) Vichithranie Madurasinghe (3438182) Ammar Chapra (14777698) Dina Abushanab (10696501) Associate Prof. Daoud Al-Badriyeh (17823431) Ashfaq Patel (16855122) |
| author_role | author |
| dc.creator.none.fl_str_mv | Dr. Rasha Kaddoura (17823428) Vichithranie Madurasinghe (3438182) Ammar Chapra (14777698) Dina Abushanab (10696501) Associate Prof. Daoud Al-Badriyeh (17823431) Ashfaq Patel (16855122) |
| dc.date.none.fl_str_mv | 2024-03-01T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2024.102376 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Beta-blocker_therapy_in_heart_failure_with_preserved_ejection_fraction_B-HFpEF_a_systematic_review_and_meta-analysis/25038278 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Mathematical sciences Statistics Adrenergic beta-antagonists Bisoprolol Carvedilol Diastolic dysfunction HFpEF Metoprolol Nebivolo |
| dc.title.none.fl_str_mv | Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Introduction</h3><p dir="ltr">While beta-blockers are considered the cornerstone of treatment for heart failure with reduced ejection fraction, the same may not apply to patients with heart failure with preserved ejection fraction (HFpEF). To date, the benefit of beta-blockers remains uncertain, and there is no current consensus on their effectiveness. This study sought to evaluate the efficacy of beta-blockers on mortality and rehospitalization among patients with HFpEF.</p><h3>Methods</h3><p dir="ltr">A systematic review and meta-analysis of randomized or observational cohort studies examined the efficacy of beta-blocker therapy in comparison with placebo, control, or standard medical care in patients with HFpEF, defined as left ventricular ejection fraction ≥50 %. The main endpoints were mortality (i.e., all-cause and cardiovascular), rehospitalization (i.e., all-cause and for heart failure) and a composite of the two.</p><h3>Results</h3><p dir="ltr">Out of the 13,189 records initially identified, 16 full-text records met the inclusion criteria and were analyzed recruiting a total of 27,188 patients. The mean age range was 62–84 years old, predominantly female, with HFpEF in which 63.4 % of patients received a beta-blocker and 36.6 % did not. The pooled analysis of included cohort studies, of variable follow-up durations, showed a significant reduction in all-cause mortality by 19 % (odds ratio (OR) 0.81; 95 % confidence interval (CI): 0.65–0.99, p = 0.044) whereas rehospitalization for heart failure (OR 1.13; 95 % CI: 0.91–1.41, p = 0.27) or its composite with all-cause mortality (OR 1.01; 95 % CI: 0.78–1.32, p = 0.92) were similar between the beta-blocker and control groups.</p><h3>Conclusion</h3><p dir="ltr">This meta-analysis showed that beta-blocker therapy has the potential to reduce all-cause mortality in patients with HFpEF based on observational studies. Nevertheless, it did not affec rehospitalization for heart failure or its composite with all-cause mortality. Large scale randomized trials are needed to clarify this uncertainty.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2024.102376" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2024.102376</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_3b6afc084a9f90dd91d92afc41cd808e |
| identifier_str_mv | 10.1016/j.cpcardiol.2024.102376 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25038278 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysisDr. Rasha Kaddoura (17823428)Vichithranie Madurasinghe (3438182)Ammar Chapra (14777698)Dina Abushanab (10696501)Associate Prof. Daoud Al-Badriyeh (17823431)Ashfaq Patel (16855122)Biomedical and clinical sciencesCardiovascular medicine and haematologyClinical sciencesPharmacology and pharmaceutical sciencesMathematical sciencesStatisticsAdrenergic beta-antagonistsBisoprololCarvedilolDiastolic dysfunctionHFpEFMetoprololNebivolo<h3>Introduction</h3><p dir="ltr">While beta-blockers are considered the cornerstone of treatment for heart failure with reduced ejection fraction, the same may not apply to patients with heart failure with preserved ejection fraction (HFpEF). To date, the benefit of beta-blockers remains uncertain, and there is no current consensus on their effectiveness. This study sought to evaluate the efficacy of beta-blockers on mortality and rehospitalization among patients with HFpEF.</p><h3>Methods</h3><p dir="ltr">A systematic review and meta-analysis of randomized or observational cohort studies examined the efficacy of beta-blocker therapy in comparison with placebo, control, or standard medical care in patients with HFpEF, defined as left ventricular ejection fraction ≥50 %. The main endpoints were mortality (i.e., all-cause and cardiovascular), rehospitalization (i.e., all-cause and for heart failure) and a composite of the two.</p><h3>Results</h3><p dir="ltr">Out of the 13,189 records initially identified, 16 full-text records met the inclusion criteria and were analyzed recruiting a total of 27,188 patients. The mean age range was 62–84 years old, predominantly female, with HFpEF in which 63.4 % of patients received a beta-blocker and 36.6 % did not. The pooled analysis of included cohort studies, of variable follow-up durations, showed a significant reduction in all-cause mortality by 19 % (odds ratio (OR) 0.81; 95 % confidence interval (CI): 0.65–0.99, p = 0.044) whereas rehospitalization for heart failure (OR 1.13; 95 % CI: 0.91–1.41, p = 0.27) or its composite with all-cause mortality (OR 1.01; 95 % CI: 0.78–1.32, p = 0.92) were similar between the beta-blocker and control groups.</p><h3>Conclusion</h3><p dir="ltr">This meta-analysis showed that beta-blocker therapy has the potential to reduce all-cause mortality in patients with HFpEF based on observational studies. Nevertheless, it did not affec rehospitalization for heart failure or its composite with all-cause mortality. Large scale randomized trials are needed to clarify this uncertainty.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2024.102376" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2024.102376</a></p>2024-03-01T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2024.102376https://figshare.com/articles/journal_contribution/Beta-blocker_therapy_in_heart_failure_with_preserved_ejection_fraction_B-HFpEF_a_systematic_review_and_meta-analysis/25038278CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/250382782024-03-01T03:00:00Z |
| spellingShingle | Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis Dr. Rasha Kaddoura (17823428) Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Mathematical sciences Statistics Adrenergic beta-antagonists Bisoprolol Carvedilol Diastolic dysfunction HFpEF Metoprolol Nebivolo |
| status_str | publishedVersion |
| title | Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis |
| title_full | Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis |
| title_fullStr | Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis |
| title_full_unstemmed | Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis |
| title_short | Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis |
| title_sort | Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Mathematical sciences Statistics Adrenergic beta-antagonists Bisoprolol Carvedilol Diastolic dysfunction HFpEF Metoprolol Nebivolo |